June 06, 2025 a 07:43 pm
MRNA: Fundamental Ratio Analysis - Moderna, Inc.
Moderna, Inc. is a pioneering biotechnology company known for its mRNA-based therapies and vaccines. It plays a significant role in combating infectious and various other diseases, bolstered by strategic partnerships. The stock's current analysis indicates a moderate valuation with room for growth as its healthcare innovations progress.
Fundamental Rating
The fundamental analysis of Moderna, Inc. shows a reasonable outlook. The overall rating is a C+. Below are the specific scores reflecting different financial aspects:
| Category | Score | |
|---|---|---|
| Overall | 2 | |
| Discounted Cash Flow | 3 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 3 | |
| Price to Earnings | 1 | |
| Price to Book | 4 |
Historical Rating
Present and past ratings provide insights into the stock's historical performance. The current date examined is 2025-06-06:
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-06-06 | 2 | 3 | 1 | 1 | 3 | 1 | 4 |
| N/A | 0 | 3 | 1 | 1 | 3 | 1 | 4 |
Analyst Price Targets
The analysts' price targets give a view on potential future price movements. Summary is captured as follows:
| High | Low | Median | Consensus |
|---|---|---|---|
| $50 | $45 | $47.5 | $47.5 |
Analyst Sentiment
The sentiment from analysts is positive, with a majority recommending to buy Moderna's stock:
| Recommendation | Count | |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 9 | |
| Hold | 9 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Moderna, Inc. presents a fair investment opportunity, with its innovative approach in the biotechnology sector and a promising pipeline of products. The fundamental ratings suggest moderate financial strength, while analysts have an optimistic future price target. The historical ratings track consistent financial performance, although potential investors should consider the volatility inherent in the biotech industry. Strategic partnerships further bolster its market position, providing both growth opportunities and risks that come with rapid technological advancements. Overall, it is considered a worthwhile addition for diversified portfolios.